Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases
Conditions: Hepatocellular Carcinoma; Liver Cancer Stage IV; Pulmonary Metastases; Cadonilimab; Bevacizumab; Cryoablation Interventions: Drug: Cadonilimab; Drug: Bevacizumab; Procedure: Cryoablation Sponsors: Sun Yat-sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 19, 2024 Category: Research Source Type: clinical trials
Evaluation of the Efficacy and Safety of Anti-angiogenic Therapy With Intravenous Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous Malformations
Conditions: Cerebral AV Malformation Interventions: Drug: Bevacizumab; Drug: Placebo Sponsors: Fondation Ophtalmologique Adolphe de Rothschild Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 19, 2024 Category: Research Source Type: clinical trials
Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma
Conditions: Liver Transplant; Hepatocellular Carcinoma Recurrent; Systemic Treatment Interventions: Drug: Systemic therapy Sponsors: Assistance Publique - H ôpitaux de Paris Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 12, 2024 Category: Research Source Type: clinical trials
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-na ïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Conditions: Metastatic Colorectal Cancer Interventions: Drug: FOLFIRI Regimen; Drug: Sotorasib; Drug: Panitumumab; Drug: Bevacizumab-awwb Sponsors: Amgen Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 12, 2024 Category: Research Source Type: clinical trials
Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer
Conditions: Metastatic Colorectal Cancer; Metastatic Gastroesophageal Adenocarcinoma; DPD Deficiency Interventions: Drug: Lonsurf; Drug: Oxaliplatin; Drug: Panitumumab; Drug: Bevacizumab; Drug: Trastuzumab; Drug: Nivolumab Sponsors: UNICANCER; Servier Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 7, 2024 Category: Research Source Type: clinical trials
Efficacy and Safety of SBRT Combined With Atezolizumab Plus Bevacizumab vs Atezolizumab Plus Bevacizumab in Treating Unresectable Advance Hepatocellular Carcinoma.
Conditions: Advanced Hepatocellular Carcinoma Interventions: Other: No intervention Sponsors: Institute of Liver and Biliary Sciences, India Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 6, 2024 Category: Research Source Type: clinical trials
Study of ZG005 in Combination With Paclitaxel ＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma
Conditions: Cervical Carcinoma Interventions: Drug: ZG005 Powder for Injection; Drug: Paclitaxel; Biological: Bevacizumab; Drug: Cisplatin; Drug: Carboplatin Sponsors: Suzhou Zelgen Biopharmaceuticals Co.,Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 5, 2024 Category: Research Source Type: clinical trials
A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular Carcinoma
Conditions: Advanced Hepatocellular Carcinoma Interventions: Biological: ZG005 Powder for Injection; Drug: Donafenib Tosilate Tablets; Biological: Bevacizumab Sponsors: Changsha Taihe Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 31, 2024 Category: Research Source Type: clinical trials
A Study to Compare the Pharmacokinetics and Safety of QL1101 and EU-Avastin ® in Healthy Volunteers
Conditions: Tumor Interventions: Drug: QL1101; Drug: Avastin ® Sponsors: Qilu Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 31, 2024 Category: Research Source Type: clinical trials
Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations
Conditions: RAS Mutation; Ras (Kras or Nras) Gene Mutation; Colorectal Cancer Recurrent; Pancreas Cancer; Lung Cancer; Melanoma; Refractory Cancer Interventions: Drug: Leflunomide; Drug: The combination of MEK inhibitor + hydroxychloroquine( plaquenil) ± bevacizumab Sponsors: N.N. Petrov National Medical Research Center of Oncology Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 29, 2024 Category: Research Source Type: clinical trials
Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer
Conditions: Metastatic Colorectal Cancer Interventions: Drug: Irinotecan Liposome; Drug: Oxaliplatin; Drug: 5-FU; Drug: LV; Drug: Bevacizumab; Drug: Cetuximab Sponsors: Shanghai Zhongshan Hospital; CSPC Ouyi Pharmaceutical Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 26, 2024 Category: Research Source Type: clinical trials
Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer
Conditions: Metastatic Colorectal Cancer; Microsatellite Stable Colorectal Carcinoma; RAS Mutation; Cadonilimab Interventions: Drug: Cadonilimab + bevacizumab + FOLFOX Sponsors: Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 23, 2024 Category: Research Source Type: clinical trials
SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases
Conditions: TNBC; Brain Metastasis Interventions: Drug: SHR-A1921 + Bevacizumab Sponsors: Fudan University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 18, 2024 Category: Research Source Type: clinical trials
Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody
Data demonstrate early activity with casdozokitug/atezolizumab/bevacizumab; 38% objective response rate including three complete responses
Data support casdozo as a promising novel immuno-oncology agent with clinical activity in liver cancer that... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 18, 2024 Category: Pharmaceuticals Source Type: clinical trials
PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC
Conditions: Colorectal Cancer; RAS Mutation; Colorectal Neoplasms; Microsatellite Stable Colorectal Carcinoma Interventions: Drug: oxaliplatin+capecitabine+bevacizumab+PD-1 antibody Sponsors: Chinese PLA General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 15, 2024 Category: Research Source Type: clinical trials
